# Northwest Biotherapeutics Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Northwest Biotherapeutics Inc). ## Overview Northwest Biotherapeutics Inc. is a U.S.-based biotechnology company focused on dendritic cell-based cancer immunotherapies. Its core programs center on DCVax-L for solid tumors such as glioblastoma and DCVax-Direct, alongside related manufacturing, process development, and clinical trial activities in the U.S. and Europe. ## Products & services • DCVax-L dendritic cell immunotherapy for solid tumors • DCVax-Direct intratumoral cancer immunotherapy • Clinical trial design and development services • Cell therapy manufacturing process development • Compassionate use access programs for DCVax therapies - **DCVax-L** (45%) — Autologous dendritic cell therapy designed for surgically resectable solid tumors, including glioblastoma. - **DCVax-Direct** (20%) — Intratumoral dendritic cell therapy program intended for tumors that can be injected directly. - **Clinical development** (15%) — Clinical trial planning, regulatory preparation, and investigator/site coordination for oncology programs. - **Manufacturing and process development** (15%) — Cell therapy manufacturing, quality control, and facility build-out supporting product supply. - **Compassionate use programs** (5%) — Expanded access treatment programs for patients seeking DCVax therapies outside trials. - DCVax-L dendritic cell immunotherapy for solid tumors - DCVax-Direct intratumoral cancer immunotherapy - Clinical trial design and development services - Cell therapy manufacturing process development - Compassionate use access programs for DCVax therapies ## Customers The company’s direct customers are not traditional commercial buyers; its programs are aimed at hospitals, clinicians, and clinical investigators that administer or study its therapies. Patients with difficult-to-treat solid tumors are the end beneficiaries, while expanded-access and compassionate-use arrangements create additional clinical channels. In practice, demand is driven by oncology centers, trial sites, and physicians seeking novel cell-based treatment options where standard therapies are limited. - **Clinical trial sites** (primary) — Hospitals and research centers that enroll patients, administer protocols, and generate clinical data for DCVax programs. - **Physician investigators** (primary) — Oncology specialists who evaluate, refer, and treat patients within study or expanded-access settings. - **Patients with solid tumors** (primary) — Patients with glioblastoma and other solid tumors who receive therapy through trials or compassionate use. - **Regulatory and research collaborators** (secondary) — Academic and institutional partners that support manufacturing, trial design, and translational work. - Oncology hospitals and clinics participating in trials - Physician investigators running DCVax clinical studies - Patients with solid tumors seeking investigational therapy - Expanded-access/compassionate-use treatment sites - Regulatory and research partners supporting development ## Geography The company is headquartered in the United States but conducts meaningful development activity in the U.K. and other European locations through subsidiaries and clinical operations. Its Sawston, U.K. facility is central to manufacturing and process development, while U.S. activities include manufacturing planning, clinical development, and expanded-access exploration. The company also references subsidiaries in the U.K., the Netherlands, and Germany, reflecting a cross-border operating footprint for a cell therapy business. - United States: corporate base, clinical development, and manufacturing planning - Sawston, U.K.: key facility for cell therapy manufacturing build-out - United Kingdom: clinical and compassionate-use activity - Netherlands and Germany: subsidiary operations supporting development - Cross-border footprint matters for regulation, logistics, and FX exposure ## Strategy The company is focused on advancing DCVax programs through clinical development, manufacturing readiness, and regulatory preparation. A major priority is building the operational infrastructure needed for cell therapy production and trial execution, while also pursuing expanded-access pathways that can generate real-world treatment experience. It is also broadening its technology base through in-licensed assets and related dendritic cell approaches that may complement the core platform. - **Advance core DCVax clinical programs** (short-term) — Clinical validation is essential for any future commercialization and partner interest. - **Complete manufacturing and facility readiness** (short-term) — Cell therapies depend on reliable GMP manufacturing, equipment, and trained staff. - **Expand access and real-world treatment experience** (medium-term) — Compassionate-use programs can support patient access and generate practical treatment data. - **Broaden the technology platform** (medium-term) — In-licensed and complementary dendritic cell technologies may extend the pipeline beyond one asset. - Advance DCVax-L toward regulatory and clinical milestones - Prepare DCVax-Direct for initial clinical testing - Build manufacturing capacity for cell therapy production - Expand compassionate-use access in the U.S. and U.K. - Integrate in-licensed dendritic cell technologies into trials ## Risks The company faces the typical risks of a pre-commercial biotechnology developer: clinical failure, regulatory delays, manufacturing setbacks, and dependence on external financing. Its cross-border operations also create execution and foreign-exchange exposure, while cell therapy development adds complexity around GMP supply, site readiness, and product consistency. Litigation, patent protection, and the ability to maintain access to capital are additional company-specific risks that can materially affect progress. - **Clinical development risk** [high] — The company depends on successful trial design, enrollment, and outcomes for DCVax programs. - **Regulatory approval risk** [high] — Cell therapies require extensive regulatory review and may face delays or requests for more data. - **Financing and going-concern risk** [critical] — The company has not established recurring operating revenue and relies on external capital. - **Manufacturing and supply-chain risk** [high] — Cell therapy production depends on specialized equipment, facilities, and qualified personnel. - **Foreign exchange risk** [medium] — A meaningful portion of activity is tied to the U.K. and other non-U.S. operations. - **Litigation risk** [medium] — Ongoing legal proceedings can create cash costs, uncertainty, and management distraction. - Clinical trial failure or delay could impair the pipeline - Regulatory approval risk is high for novel cell therapies - Manufacturing scale-up is complex and capital intensive - Funding dependence creates going-concern and dilution risk - Cross-border operations add FX and execution risk - Litigation and IP disputes can consume cash and management time ## Accounting As a development-stage biotech company, the most important accounting judgments relate to R&D expense, accrued clinical and regulatory costs, stock-based compensation, and derivative liabilities. The company also has foreign-currency effects from its U.K. operations and may face valuation sensitivity in estimates tied to warrants, derivatives, and other fair-value measurements. Because it is pre-revenue, expense timing and capitalization judgments can materially affect reported losses and period-to-period comparability. - **Research and development expense** — Period-to-period volatility in operating results - **Accrued expenses** — Potential true-up adjustments in later periods - **Derivative liabilities** — Earnings volatility unrelated to core operations - **Stock-based compensation** — Affects operating expense and dilution analysis - **Foreign currency translation and transaction gains/losses** — Non-operating volatility in reported results - R&D expense timing affects reported losses and trial comparability - Accrued clinical and regulatory costs require management estimates - Derivative liabilities can create fair-value volatility - Stock-based compensation affects operating expense and equity - Foreign currency gains/losses reflect U.K.-linked operations --- *Last updated: 2026-04-29T04:40:31.994407+00:00*